Brigid Bondoc, a partner in the FDA + Healthcare Regulatory and Compliance group, will be a panelist at the MassBio event “The FDA Modernization Act: Moving from In Vivo to In Vitro Drug Testing.”
The FDA Modernization Act, signed into law by President Biden as part of a larger spending package, empowers drug developers to use alternative methods to animal testing to investigate the safety and effectiveness of a new drug. Moving away from traditional animal models to in vitro studies will impact drug development, though questions remain about how quickly the industry will pivot and the extent to which alternatives can replace lab animals. The panel will discuss the FDA’s move to no longer require animal testing, what alternative methods are out there (such as organs‑on-a-chip and human iPSC-derived cells), how advances in artificial intelligence and machine learning will play a role, and how soon this policy move will lead to faster, more effective therapeutic development.
For more information, please visit the MassBio website.